Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) combined with endocrine therapy are the preferred choice for first-line treatment of patients with HR<sup>+</sup>/HER2<sup>-</sup> locally advanced/metastatic breast cancer (aBC). Here, CDK4 is linked to aneurysmal bone cyst.